Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Reference
Endpoint:
basic toxicokinetics, other
Remarks:
expert QSAR report
Type of information:
(Q)SAR
Adequacy of study:
supporting study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
results derived from a (Q)SAR model, with limited documentation / justification, but validity of model and reliability of prediction considered adequate based on a generally acknowledged source
Executive summary:

Incentive

Evaluation of the toxicokinetic properties (i.e. absorption, metabolism, distribution and elimination) of the substance is a requirement. The information can contribute in the understanding of the toxicological profile and assist in testing

strategy and study design.

Objective

The purpose of this study was to assess the toxicokinetic properties of ethylene dibenzoate (EGDB, CAS 94-49-5).

Methods

The toxicokinetic properties of EGDB are evaluated using free and commercially available computerized models as well as available study information on the substance itself.

Conclusions

EGDB is a mono-constituent of at least 99.4% purity and has a molecular weight of 270.28 g/mole. It is a solid at room temperature. Based on information from property profiling as well on information on studies on EGDB, the following statements can be made:

- Oral absorption: the bioavailability of EGDB, following dissociation of the salt in the Gastro- Intestinal tract, is considered to be high via oral route. A provisional absorption rate of 100% is set for the oral route.

- Dermal absorption: Dermal absorption of EGDB is expected to be high. A provisional absorption rate of 100% is set for the dermal route.

- Respiratory absorption: Likelihood of exposure via inhalation is low considering the very low vapor pressure. Exposures are only possibly to aerosols that will deposit mainly in upper airways, and will be subsequently swallowed after mucociliary transportation to pharynx. No principal difference is therefore expected in absorption between exposures via inhalation route and oral route as high in respiratory tract. Absorption via inhalation therefore also set to 100%.

- It is predicted that EGDB is rapidly absorbed, distributed over the whole body and excreted again

- EGDB has no bioaccumulation potential (LogPow 3.75 (just above 3) and readily biodegradable).

Description of key information

Due to lack of quantitative data, absorption rates of 100% are indicated for all three routes. This basically indicates that, although the absorption is probably low, there is likely no significant difference expected in absorption between oral, dermal and inhalation route. Available studies (readily biodegradable, low log kow) do not indicate a concern for bioaccumulation.

EGDB is a mono-constituent of at least 99.4% purity and has a molecular weight of 270.28 g/mole. It is a solid at room temperature.

Based on information from property profiling as well on information on studies on EGDB, the following statements can be made:

- Oral absorption: the bioavailability of EGDB, following dissociation of the salt in the Gastro- Intestinal tract, is considered to be high via oral route. A provisional absorption rate of 100% is set for the oral route.

- Dermal absorption: Dermal absorption of EGDB is expected to be high. A provisional absorption rate of 100% is set for the dermal route.

- Respiratory absorption: Likelihood of exposure via inhalation is low considering the very low vapor pressure. Exposures are only possibly to aerosols that will deposit mainly in upper airways, and will be subsequently swallowed after mucociliary transportation to pharynx. No principal difference is therefore expected in absorption between exposures via inhalation route and oral route as high in respiratory tract. Absorption via inhalation therefore also set to 100%.

- It is predicted that EGDB is rapidly absorbed, distributed over the whole body and excreted again

- EGDB has no bioaccumulation potential (LogPow 3.75 (just above 3) and readily biodegradable).

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - oral (%):
100
Absorption rate - dermal (%):
100
Absorption rate - inhalation (%):
100

Additional information

From a combined OECD 422/408 study, there were some concerns raised of possible effects on thyroid function, based on a decreased T4 at 1000 mg/kg. Further studies (OECD 414 and neurodevelopmental toxicity OECD 426) did not confirm the concerns raised and confirmed a NOAEL of 1000 mg/kg bw.

Ethyleen glycol dibenzoate (EGDB) is expected to be metabolized relative quickly over the two ester bonds in analogy of the comparable substance DEGDB (Oxydiethylene dibenzoate, CAS 120-55-8).

In an OECD 417 study, virtually all DEGDB was absorbed, metabolized and excreted in urine with 24 hours of administration. Metabolism involved hydrolysis of the ester bonds to benzoic acid, which was conjugated with either glycine (major pathway) or glucuronic acid (minor pathway) prior to excretion.

The same can be expected for EGDB.

All three substances, benzoic acid, EGDB and DEGDB show a NOAEL of 1000 mg/kg bw/day from repeated dose toxicity testing.